SEC Form 4 · accession 0001417952-26-000002
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert N Fried
Officer — Chief Executive Officer · Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 8, 2026 · 5:16 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001386570
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | A | 1,106 | $2.71 | A | 1,060,087 | D | |
| Common Stock | holding | — | — | — | 95,001 | I | By Fried-Travis Revocable Trust U/A Dated 06/02/1999 | |
| Common StockF2 | holding | — | — | — | 250,000 | I | By US Trust Co. of Delaware Trustee of The Jeremy W Fried 2020 Irrevocable Trust dated 02/26/2020 | |
| Common StockF2 | holding | — | — | — | 250,000 | I | By US Trust Co. of Delaware Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020 | |
| Common StockF3 | holding | — | — | — | 12,746 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d).
- F2The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- F36,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried.